Novartis has announced plans to divide its pharmaceuticals division into two business units, in a restructure that also sees the departure of current division head and chief executive David Epstein.
Under the new structure, Novartis Pharmaceuticals and Novartis Oncology will form the Innovative Medicines Division at the Swiss drugmaker, joining the firm’s generics/biosimilars unit Sandoz and eye unit Alcon.
The move brings some key changes at the top: Epstein has decided to leave Novartis “and explore new challenges from the US”; Paul Hudson, currently executive vice president, North America, at AstraZeneca, will lead Novartis Pharmaceuticals; and Bruno Strigini, currently head of Novartis’ oncology segment, will also lead the Novartis Oncology business unit.
The firm said it expects that the changes, which ride on the back of the successful integration of the oncology assets from GlaxoSmithkline, will help drive its growth and innovation strategy, “with an increased focus and improved execution” for both business units.
Last year the group sold off its animal health division to Eli Lilly and vaccines unit to GSK, while bringing on board GSK’s oncology assets, under a drive to streamline focus and operations.
“A split makes sense because oncology now has critical mass, following the GSK deal, and oncology is in many ways becoming a differentiated business from the rest of pharmaceuticals,” said Mick Cooper, an analyst at equity research firm Trinity Delta, reports Reuters.
By Selina McKee
Source: Pharma Times
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.